{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:59:19Z","timestamp":1791266359407,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Vaccines and Diagnostics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.vaccine.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T04:00:31Z","timestamp":1345003231000},"page":"6436-6443","source":"Crossref","is-referenced-by-count":23,"title":["A prospective observational safety study on MF59\u00ae adjuvanted cell culture-derived vaccine, Celtura\u00ae during the A\/H1N1 (2009) influenza pandemic"],"prefix":"10.1016","volume":"30","author":[{"given":"Humberto","family":"Reynales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Astudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"de Valli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Velentgas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Fari\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sales-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.08.005_bib0005","unstructured":"Council for International Organizations of Medical Sciences. Benefit-risk balance for marketed drugs: evaluating safety signals internet. Geneva, Switzerland; 1998 cited 2012 July 5. Available from: <http:\/\/www.cioms.ch\/publications\/g4-benefit-risk.pdf>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1086\/656578","article-title":"Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults","volume":"51","author":"Frey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1586\/erv.09.31","article-title":"Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines)","volume":"8","author":"Doroshenko","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2012.08.005_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/fmb.10.161","article-title":"Safety of MDCK cell culture based influenza vaccines","volume":"6","author":"Gregersen","year":"2011","journal-title":"Future Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.08.005_bib0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12325-010-0043-4","article-title":"Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A\/H1N1v vaccine in Japanese children","volume":"27","author":"Yasuda","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0030","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.vaccine.2008.11.003","article-title":"Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial","volume":"27","author":"Groth","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0035","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.vaccine.2011.02.097","article-title":"Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination","volume":"29","author":"Parretta","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0040","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2011.02.068","article-title":"Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of a vaccination campaign in an Italian health district","volume":"29","author":"Cristiani","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O\u2019Hagan","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0055","unstructured":"European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine internet. London, UK; 2009 September cited 2011 September 22. Available from: <http:\/\/www.emea.europa.eu\/pdfs\/human\/pandemicinfluenza\/35938109en.pdf>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0060","unstructured":"Pan American Health Organization. Response to Pandemic (H1N1) 2009 in the Americas: lessons and challenges (2010). Internet 2009. Cited 2011 December 16. Available from: <http:\/\/new.paho.org\/hq\/dmdocuments\/2010\/Lessons%20learned_2010_H1N1.pdf>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0065","unstructured":"European Commission the Rules Governing Medicinal Products in the European Union Guidelines on Pharmacovigilance for Medicinal Products for Human Use Internet. 2008. Cited 2011 September 22. Available from: <http:\/\/ec.europa.eu\/health\/documents\/eudralex\/vol-9\/index_en.htm>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0070","unstructured":"World Health Organization. Pandemic influenza preparedness and response: a WHO guidance document. Internet. 2010. Cited 2011 December 13. Available from: <http:\/\/whqlibdoc.who.int\/publications\/2009\/9789241547680_eng.pdf>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0075","unstructured":"International Conference on Harmonisation. Guideline for good clinical practice E6(R1) Internet. June 1996. Cited 2012 July 06. Available from: <http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0080","unstructured":"United States Centers for Disease Control and Prevention. Interim recommendations for clinical use of influenza diagnostic tests during the 2009\u201310 influenza season internet. Atlanta; 2009 September cited 2011 September 22. Available from: <http:\/\/www.cdc.gov\/h1n1flu\/guidance\/diagnostic_tests.htm>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0085","unstructured":"Council for International Organizations of Medical Sciences. CIOMS\/WHO Working Group on Vaccine Pharmacovigilance: Vaccination Failure Internet. Geneva; 2008 April cited 2011 September 22. Available from: <http:\/\/cioms.ch\/activities\/frame_vaccpharmapospaper.htm>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0090","series-title":"Statistical methods for rates and proportions","author":"Fleiss","year":"2003"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0100","unstructured":"Brighton Collaboration. Brighton collaboration available case definitions internet. 2010 cited 2011 September 22. Available from <https:\/\/brightoncollaboration.org\/public\/what-we-do\/standards\/case-definitions\/available-definitions.html>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0105","unstructured":"International League Against Epilepsy. Task force on classification and terminology internet. 2011 cited 2011 September 22. Available from: <http:\/\/www.ilae-epilepsy.org\/Visitors\/Centre\/ctf\/index.cfm>."},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2012.08.005_bib0110","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","article-title":"Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis","volume":"120","author":"Barkhof","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa011341","article-title":"A longitudinal study of abnormalities on MRI and disability from multiple sclerosis","volume":"346","author":"Brex","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.1780330808","article-title":"The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis","volume":"33","author":"Calabrese","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0125","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0130","first-page":"489","article-title":"Proposal for a revised clinical and encephalographic classification of epileptic seizures","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0135","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.WNL.0000082654.99838.EF","article-title":"The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"61","author":"Frohman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1542\/peds.88.5.881","article-title":"Risk of seizures after measles\u2013mumps\u2013rubella immunization","volume":"88","author":"Griffin","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0145","series-title":"Nelson textbook of pediatrics","article-title":"The nervous system","author":"Haslam","year":"1996"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0150","first-page":"111","article-title":"Classification of the systemic vasculitides: antineutrophil cytoplasmic antibodies, consensus and controversy","volume":"16","author":"Hoffman","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0160","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7326\/0003-4819-129-1-199807010-00012","article-title":"Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2. Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity","volume":"129","author":"Langford","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0170","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/rheumatology\/ken079","article-title":"Evaluation of a new algorithm in classification of systemic vasculitis","volume":"47","author":"Liu","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2008-1071488","article-title":"Workshop on neurologic complications of pertussis and pertussis vaccination","volume":"21","author":"Menkes","year":"1990","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0185","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00002281-199701000-00002","article-title":"Multisystem interactions in the pathogenesis of vasculitis","volume":"9","author":"Weyand","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0200","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0205","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0210","unstructured":"World Health Organization. Geneva World Health Organization Pandemic (H1N1) 2009 Situation Updates Internet. Geneva; 2009\u20132010 cited 2011 September 22. Available from: <http:\/\/www.who.int\/csr\/disease\/swineflu\/updates\/en\/>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0215","unstructured":"Istituto de Salud Publica, Chile: La Secci\u00f3n de Virus Respiratorios del Instituto de Salud P\u00fablica inform\u00f3 los resultados. A\u00f1o 2010: S\u00f3lo 326 casos de influenza pand\u00e9mica confirmados por el Instituto de Salud P\u00fablica Internet. 2010 cited 2011 December 16. Available from: <http:\/\/www.ispch.cl\/>."},{"issue":"42","key":"10.1016\/j.vaccine.2012.08.005_bib0220","doi-asserted-by":"crossref","first-page":"19362","DOI":"10.2807\/ese.14.42.19362-en","article-title":"Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI)","volume":"14","author":"Oliveira","year":"2009","journal-title":"Euro Surveill"},{"issue":"30","key":"10.1016\/j.vaccine.2012.08.005_bib0225","doi-asserted-by":"crossref","first-page":"19284","DOI":"10.2807\/ese.14.30.19284-en","article-title":"Epidemiologic analysis of the laboratory-confirmed cases of influenza A(H1N1)v in Colombia","volume":"14","author":"Castro-Jimenez","year":"2009","journal-title":"Euro Surveill"},{"issue":"6","key":"10.1016\/j.vaccine.2012.08.005_bib0230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1086\/650750","article-title":"Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile","volume":"50","author":"Torres","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2012.08.005_bib0235","doi-asserted-by":"crossref","first-page":"19299","DOI":"10.2807\/ese.14.32.19299-en","article-title":"Epidemiological and transmissibility analysis of influenza A(H1N1)v in a southern hemisphere setting: Peru","volume":"14","author":"Munayco","year":"2009","journal-title":"Euro Surveill"},{"issue":"35","key":"10.1016\/j.vaccine.2012.08.005_bib0240","doi-asserted-by":"crossref","first-page":"19323","DOI":"10.2807\/ese.14.35.19323-en","article-title":"Epidemiological analysis of the influenza A(H1N1)v outbreak in Bolivia, May\u2013August 2009","volume":"14","author":"Gianella","year":"2009","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0245","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1016\/j.vaccine.2010.05.031","article-title":"The 2009 A (H1N1) influenza virus pandemic: a review","volume":"28","author":"Girard","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0250","unstructured":"European Medicines Agency. Twenty-second pandemic pharmacovigilance update Internet. 2010 August cited 2011 September 22. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/08\/WC500095870.pdf>."},{"key":"10.1016\/j.vaccine.2012.08.005_bib0255","series-title":"Influenza vaccines for the future","article-title":"Cell culture-derived influenza vaccines","author":"Dormitzer","year":"2011"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0260","unstructured":"National Institute for Health and Welfare. National Narcolepsy Task Force Interim Report. Internet. 2011 January cited 2011 October 24. Available from: <http:\/\/www.thl.fi\/thl-client\/pdfs\/dce182fb-651e-48a1-b018-3f774d6d1875>."},{"issue":"3","key":"10.1016\/j.vaccine.2012.08.005_bib0265","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.22587","article-title":"Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China","volume":"70","author":"Han","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0270","first-page":"15","article-title":"Pandemic influenza A (H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009\u20132010","author":"Wichmann","year":"2010","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2012.08.005_bib0275","first-page":"10","article-title":"The first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration","author":"Poggensee","year":"2010","journal-title":"BMC Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12011711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12011711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T15:58:00Z","timestamp":1643212680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12011711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":55,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0264410X12011711"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.08.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}